Why Fosun Pharma’s AriBio deal could reshape the race for oral Alzheimer’s therapies
Alzheimer’s drugs are moving beyond antibodies. Fosun Pharma’s AR1001 option turns one Phase 3 readout into a global commercial test.
Pharma & Biotech
Pharma & Biotech
What Clene Inc.’s FDA feedback reveals about the future of surrogate endpoints in ALS trials
Can biomarker-driven approvals transform ALS drug development? Explore how Clene Inc.’s FDA feedback on CNM-Au8 could accelerate innovation.
Pharma & Biotech
Why BioVie Inc.’s Phase 2 bezisterim data could shift the Parkinson’s disease treatment paradigm
Explore how BioVie Inc.’s bezisterim could reshape Parkinson’s treatment strategies ahead of Phase 2 data. Find out what it means for the industry.
Pharma & Biotech
NeuroSense expands Alzheimer’s IP with U.S. patent, but all eyes are on RoAD trial results
NeuroSense gains a U.S. patent for PrimeC in Alzheimer’s disease. Find out what it means ahead of key trial results due in early 2026.
Pharma & Biotech
What Neurizon’s entry into the HEALEY ALS trial means for the future of NUZ-001
Neurizon Therapeutics Limited has received clearance from the United States Food and Drug Administration for its investigational therapy NUZ-001 to be included in the HEALEY ALS Platform Trial, a globally recognized adaptive trial framework for amyotrophic lateral sclerosis. The decision formally designates NUZ-001 as Regimen I in the platform, allowing clinical site activation and study